{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:40:54Z","timestamp":1791657654516,"version":"4.3.4"},"reference-count":184,"publisher":"Wiley","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Peptide Science"],"abstract":"<jats:p>Peptides exhibit significant specificity and effective interaction with therapeutic targets, positioning themselves as key players in the global pharmaceutical market. They offer potential treatments for a wide range of diseases, including those that pose significant challenges. Notably, the peptide trofinetide (Daybue) marked a groundbreaking achievement by providing the first\u2010ever cure for Rett syndrome, and several peptides have secured FDA approval as first\u2010in\u2010class medications. Furthermore, peptides are expanding their presence in areas traditionally dominated by either small or large molecules. A noteworthy example is the FDA approval of motixafortide (Aphexda) as the first peptide\u2010based chemokine antagonist. Here, the focus will be on the analysis of FDA\u2010approved peptides, particularly those targeting cardiovascular diseases, human immunodeficiency, central nervous system diseases, and various other intriguing classes addressing conditions such as osteoporosis, thrombocytopenia, Cushing's disease, and hypoglycemia, among others. The review will explore the chemical structures of the peptides, their indications and modes of action, the developmental trajectory, and potential adverse effects.<\/jats:p>","DOI":"10.1002\/psc.3627","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:25:40Z","timestamp":1718666740000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond"],"prefix":"10.1002","author":[{"given":"Othman","family":"Al Musaimi","sequence":"first","affiliation":[{"name":"School of Pharmacy  Newcastle upon Tyne UK"},{"name":"Department of Chemical Engineering Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29030585"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14030264"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031038"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201000904\u20104"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02697"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.10.003"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592514"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425\u2010019\u20100586\u20100"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051032"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja00897a025"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726\u2010017\u20102516\u20100"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.454"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1039\/c9gc03982a"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2GC02319A"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.2c00132"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.02.024"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1133"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.09.23"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3448"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097\u20100282(2000)55:3<227::AID\u2010BIP50>3.0.CO;2\u20107"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph11020042"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1039\/D1CS00271F"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.0c03705"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10989\u2010018\u20109757\u2010y"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471140864.ps1806s23"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471140864.ps2806s76"},{"key":"e_1_2_11_28_1","unstructured":"Unveiling the Phenomenal Rise of Peptide Therapeutics: A Whopping 10.8% CAGR Propels Market Value to US$ 106.0 Billion by 2033.2023.https:\/\/www.pharmiweb.com\/press-release\/2023-07-25\/unveiling-the-phenomenal-rise-of-peptide-therapeutics-a-whopping-108-cagr-propels-market-value-to"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4020492"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.170939"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000116223.97436.e5"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010018\u20100925\u2010x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900063"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_11_35_1","unstructured":"Integrilin Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20718_INTEGRILIN_APPROV.PDF"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002\u20109149(97)00572\u20109"},{"key":"e_1_2_11_37_1","unstructured":"Bivalirudin Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20873_Angiomax_prntlbl.pdf"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527\u20103466.2005.tb00177.x"},{"key":"e_1_2_11_39_1","unstructured":"Bivalirudin Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20873_Angiomax_Approv.pdf"},{"key":"e_1_2_11_40_1","unstructured":"Nesiritide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/20-920_Natrecor_prntlbl.pdf"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0377\u20101237(05)80072\u20103"},{"key":"e_1_2_11_42_1","unstructured":"Nesiritide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/20-920_Natrecor_Approv.pdf"},{"key":"e_1_2_11_43_1","unstructured":"Icatibant Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022150s000lbl.pdf"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2010.03642.x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978\u20100\u2010444\u201056378\u20101.00059\u20109"},{"key":"e_1_2_11_46_1","unstructured":"Icatibant Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022150Orig1s000Approv.pdf"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.21.2.259"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.112.006809"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978\u20100\u201012\u2010385095\u20109.00241\u20104"},{"key":"e_1_2_11_50_1","unstructured":"Captopril Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/018343s084lbl.pdf"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102249.2000.01323.x"},{"key":"e_1_2_11_52_1","unstructured":"Captopril Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2011\/018343s083ltr.pdf"},{"key":"e_1_2_11_53_1","unstructured":"Enalapril Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/018998s079lbl.pdf"},{"issue":"1","key":"e_1_2_11_54_1","first-page":"27","article-title":"Enalapril, a nonsulfhydryl angiotensin\u2010converting enzyme inhibitor","volume":"4","author":"Vlasses P.H.","year":"1985","journal-title":"Clin Pharm."},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199243030\u201000005"},{"key":"e_1_2_11_56_1","unstructured":"Enalapril Approval Letter.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/018998_Vasotec.cfm#:~:text=Approval%20Date%3A%2012%2F24%2F1985"},{"key":"e_1_2_11_57_1","unstructured":"Lisinopril Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/19-558s043_Prinivil_prntlbl.pdf"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199652040\u201000011"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.07.026"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.116.303587"},{"key":"e_1_2_11_61_1","unstructured":"Lisinopril Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/19-558s043_Prinivil_approv.pdf"},{"key":"e_1_2_11_62_1","unstructured":"The Global HIV and AIDS Epidemic.https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/global-statistics"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2009.07.003"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201040125\u20104"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl2162"},{"key":"e_1_2_11_66_1","unstructured":"Enfuvirtide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21481_Fuzeon_Prntlbl.pdf"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1331"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11262\u2010007\u20100098\u20108"},{"key":"e_1_2_11_69_1","unstructured":"Enfuvirtide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21481_Fuzeon_Approv.pdf"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1039\/D4TB00019F"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060810"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13050714"},{"key":"e_1_2_11_73_1","unstructured":"Ziconotide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-060_Prialt_Prntlbl.PDF"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.4161\/chan.4.6.12869"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00023.2013"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13789"},{"key":"e_1_2_11_77_1","unstructured":"Ziconotide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-060_Prialt_Approv.PDF"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002398\u20101"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.12.003"},{"key":"e_1_2_11_80_1","unstructured":"Daybue Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217026s000lbl.pdf"},{"key":"e_1_2_11_81_1","unstructured":"Teriparatide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-318_FORTEO_Prntlbl.pdf"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070171"},{"key":"e_1_2_11_83_1","volume-title":"StatPearls","author":"Vall H","year":"2023"},{"key":"e_1_2_11_84_1","unstructured":"Teriparatide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-318_FORTEO_Approv.pdf"},{"key":"e_1_2_11_85_1","unstructured":"Abaloparatide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208743lbl.pdf"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1300"},{"key":"e_1_2_11_87_1","volume-title":"StatPearls","author":"Akel M","year":"2023"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107363118"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.05.024"},{"key":"e_1_2_11_90_1","unstructured":"Abaloparatide Approval Letter.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208743Orig1s000Approv.pdf"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666171205150310"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.10.005"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2018.01.005"},{"issue":"3","key":"e_1_2_11_94_1","first-page":"154","article-title":"Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic Constipation","volume":"38","author":"Thomas R.H.","year":"2013","journal-title":"Pharm Ther."},{"key":"e_1_2_11_95_1","unstructured":"Linaclotide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/202811Orig1s000ltr.pdf"},{"key":"e_1_2_11_96_1","unstructured":"Linaclotide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202811s013lbl.pdf"},{"key":"e_1_2_11_97_1","unstructured":"Plecanatide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208745lbl.pdf"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100718\u20100"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.08.007"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1594"},{"key":"e_1_2_11_101_1","unstructured":"Plecanatide Approval letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/208745orig1s000ltr.pdf"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u2010065X.2001.1800103.x"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978\u2010012088451\u20103.50021\u20101"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2015.02.001"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040399"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25960"},{"key":"e_1_2_11_107_1","unstructured":"Empaveli Drug Label.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215014s000lbl.pdf"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201033003\u20107"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01851"},{"key":"e_1_2_11_110_1","unstructured":"Empaveli Approval Letter.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/215014Orig1s000ltr.pdf"},{"key":"e_1_2_11_111_1","unstructured":"Zilbrysq Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2016.04.002"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S108490"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001726\u2010y"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010019\u20100079\u2010y"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213920"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201002\u2010412080"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.02.011"},{"key":"e_1_2_11_119_1","unstructured":"Galtiramer Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020622s057lbl.pdf"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.02.003"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404887101"},{"key":"e_1_2_11_122_1","unstructured":"Glatiramer Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/020622Orig1s114ltr.pdf"},{"key":"e_1_2_11_123_1","unstructured":"Romiplostim Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125268s077lbl.pdf"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S299591"},{"key":"e_1_2_11_125_1","unstructured":"Romiplostim Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/125268Orig1s169ltr.pdf"},{"key":"e_1_2_11_126_1","unstructured":"Ecallantide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125277s081lbl.pdf"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.2147\/jbm.S66825"},{"key":"e_1_2_11_128_1","unstructured":"Pasireotide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/200677Orig1s000Lbl.pdf"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2007.09.006"},{"key":"e_1_2_11_130_1","unstructured":"Pasireotide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/200677Orig1s000Approv.pdf"},{"key":"e_1_2_11_131_1","unstructured":"Peginesatide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202799Orig1s000Lbl.pdf"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1218467"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.2165\/00151829\u2010200504020\u201000008"},{"key":"e_1_2_11_134_1","unstructured":"Lucinactant Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/021746Orig1s000Lbl.pdf"},{"key":"e_1_2_11_135_1","unstructured":"Lucinactant Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/021746Orig1s000Approv.pdf"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010013\u20100070\u2010y"},{"key":"e_1_2_11_137_1","unstructured":"Teduglutide Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203441Orig1s000lbl.pdf"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32832d23cd"},{"key":"e_1_2_11_139_1","unstructured":"Teduglutide Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203441Orig1s000Approv.pdf"},{"key":"e_1_2_11_140_1","unstructured":"Ombitasvir Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100753\u2010x"},{"key":"e_1_2_11_142_1","unstructured":"Ombitasvir Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206619Orig1s000Approv.pdf"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068007"},{"key":"e_1_2_11_144_1","unstructured":"Etelcalcetide Drug label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208325Orig1s000Lbledt.pdf"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223\u2010017\u20100319\u20107"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft417"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468"},{"key":"e_1_2_11_148_1","unstructured":"Etelcalcetide Approval Letter.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208325Orig1s000Approv.pdf"},{"key":"e_1_2_11_149_1","unstructured":"Dasiglucagon Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214231s000lbl.pdf"},{"key":"e_1_2_11_150_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00492.2002"},{"key":"e_1_2_11_151_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010021\u201003183\u20100"},{"key":"e_1_2_11_152_1","unstructured":"Dasiglucagon Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/214231Orig1s000ltr.pdf"},{"key":"e_1_2_11_153_1","unstructured":"Lupkynis Drug Label.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213716s000lbl.pdf"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00578\u2010x"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.4137\/OED.S7995"},{"key":"e_1_2_11_156_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2092470"},{"key":"e_1_2_11_157_1","unstructured":"Lupkynis Approval Letter.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/213716Orig1s000ltr.pdf"},{"key":"e_1_2_11_158_1","unstructured":"Difelikefalin Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214916s000lbl.pdf"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001619\u20106"},{"key":"e_1_2_11_160_1","unstructured":"Difelikefalin Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214916Orig1s000Approv.pdf"},{"key":"e_1_2_11_161_1","unstructured":"Odevixibat Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215498s000lbl.pdf"},{"key":"e_1_2_11_162_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001594\u2010y"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102019\u2010234185"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00931"},{"key":"e_1_2_11_165_1","unstructured":"Odevixibat Approval Letter. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/215498Orig1s000ltr.pdf"},{"key":"e_1_2_11_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001623\u2010w"},{"key":"e_1_2_11_167_1","unstructured":"Voxzogo Drug Label.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214938s000lbl.pdf"},{"key":"e_1_2_11_168_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115573"},{"key":"e_1_2_11_169_1","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.24479"},{"key":"e_1_2_11_170_1","unstructured":"Voxzogo Approval Letter.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/214938Orig1s000ltr.pdf"},{"key":"e_1_2_11_171_1","unstructured":"Terlivaz Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022231s000lbl.pdf"},{"key":"e_1_2_11_172_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002147"},{"key":"e_1_2_11_173_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102044.2004.03877.x"},{"key":"e_1_2_11_174_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H373"},{"key":"e_1_2_11_175_1","unstructured":"Terlivaz Approval Letter.https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010treatment\u2010improve\u2010kidney\u2010function\u2010adults\u2010hepatorenal\u2010syndrome"},{"key":"e_1_2_11_176_1","unstructured":"Elucirem Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216986s000lbl.pdf"},{"key":"e_1_2_11_177_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.8b00363"},{"key":"e_1_2_11_178_1","unstructured":"Gadopiclenol: positive results for Phase III clinical trials.https:\/\/www.guerbet.com\/news\/gadopiclenol-positive-results-for-phase-iii-clinical-trials"},{"key":"e_1_2_11_179_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010023\u201001962\u2010w"},{"key":"e_1_2_11_180_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1711884"},{"key":"e_1_2_11_181_1","unstructured":"Aphexda Drug Label. chrome\u2010extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217159s000lbl.pdf"},{"key":"e_1_2_11_182_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231174304"},{"key":"e_1_2_11_183_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020145"},{"key":"e_1_2_11_184_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020222"},{"key":"e_1_2_11_185_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030336"}],"container-title":["Journal of Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psc.3627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:25:52Z","timestamp":1718666752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/psc.3627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":184,"alternative-id":["10.1002\/psc.3627"],"URL":"https:\/\/doi.org\/10.1002\/psc.3627","archive":["Portico"],"relation":{},"ISSN":["1075-2617","1099-1387"],"issn-type":[{"value":"1075-2617","type":"print"},{"value":"1099-1387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"2024-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3627"}}